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Abstract 
Background 
Recent research using data-driven cluster analysis has proposed five 
subgroups of diabetes with differences in diabetes progression and risk of 
complications.  We aimed to compare the clinical utility of this subgroup-based 
approach for predicting patient outcomes with an alternative strategy of 
developing models for each outcome using simple patient characteristics. 
 
Methods 
We identified clusters in the ADOPT (n=4,351) trial cohort using the cluster 
analysis reported by Ahlqvist and colleagues (Lancet Diabetes Endocrinology 
2018;6:361-69). Differences between clusters in glycaemic and renal 
progression were evaluated, and contrasted with stratification using simple 
continuous clinical features (respectively, age at diagnosis and baseline renal 
function). We tested the performance of a strategy of selecting glucose-lowering 
therapy using clusters with one combining simple clinical features (sex, BMI, 
age at diagnosis, baseline HbA1c) in an independent trial (RECORD 
(n=4,447)).   
 
Findings 
Clusters identified in trial data were similar to those described in the original 
study. Clusters showed differences in glycaemic progression, but a model with 
age at diagnosis alone explained a similar amount of variation in progression. 
We found differences in CKD incidence between clusters however baseline 
eGFR was a better predictor of time to CKD. Clusters differed in glycaemic 
response, with a particular benefit for cluster 3 (insulin-resistant) with 
thiazolidinediones and cluster 5 (older) with sulfonylureas. However simple 
clinical features outperformed clusters to select therapy for individual patients. 
 
Interpretation 
The proposed data-driven clusters differ in diabetes progression and treatment 
response, but models based on simple continuous clinical features are more 
useful to stratify patients. This suggests precision medicine in type 2 diabetes is 
likely to have most clinical utility if based on an approach of using specific 
phenotypic measures to predict specific outcomes, rather than assigning 
patients into subgroups. 
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Research in context 
 
Evidence before this study 
A recent study published in Lancet Diabetes and Endocrinology proposed a 
novel substratification of diabetes, using a data-driven cluster analysis in 
Scandinavian registry data to identify five reproducible subgroups of adult-onset 
diabetes. The authors went on to show differences between the clusters in 
disease progression and risk of complications in observational follow-up. The 
authors suggested the clusters might help with therapy selection in the future 
but did not test whether the clusters could inform therapy choice. We searched 
Scopus, Web of Science, and Google Scholar to track the citations of the 
original study, searching for follow-up studies assessing the reproducibility, 
clinical utility and role in treatment selection of the proposed data-driven 
clusters up to January 1, 2019. We identified a study that identified similar 
clusters in Chinese and a small mixed American population but did not examine 
any aspect of clinical utility as clinical follow-up was not available. A second 
study of Danish patients applied similar cluster analysis and, with duration of 
diabetes as an additional input variable, identified five subgroups of type 2 
diabetes that differed to those in the original study, and differed in the 
prevalence of diabetes complications. No studies were found that tested the 
clinical utility and particularly the role in treatment of the proposed cluster-based 
approach. 
 
Added value of this study 
This study takes forward the concept of heterogeneity in type 2 diabetes, by 
testing the clinical utility of the data-driven cluster approach proposed by 
Ahlqvist and colleagues. The cluster analysis was repeated, and differences by 
cluster in disease progression and treatment response were evaluated in newly 
diagnosed participants in the ADOPT trial with randomised, protocol-driven 
follow-up data available. We found the clusters were reproducible and did differ 
in progression and treatment response. However, simpler clinical measures 
were as or more useful than the clusters for stratifying each outcome assessed.  
 
Implications of all the available evidence 
Patients with type 2 diabetes differ in treatment response and risk of disease 
progression, raising the possibility of a practical, clinically orientated stratified 
approach in the near future. Our study suggests a ‘prediction model’ approach, 
combining phenotypic measures to predict specific outcomes for individual 
patients, is likely to have greater clinical utility than approaches that use clinical 
features to assign individuals into subgroups. 
  
Introduction 
Type 2 diabetes is a heterogeneous multifactorial condition, comprising 90-95% 
of all diabetes and affecting over 400 million people worldwide. There is 
currently great interest in better characterising the heterogeneity in type 2 
diabetes, and in exploiting this heterogeneity to improve care and outcomes for 
individuals with type 2 diabetes.(1-3)  
In a recent study, Ahlqvist and colleagues identified five replicable clusters of 
individuals with diabetes in Scandinavian registry data.(4) The smallest cluster 
was defined by the presence of glutamic acid decarboxylase (GAD) 
autoantibody positivity, regardless of other characteristics (Cluster 1: severe 
autoimmune diabetes (SAID)). Four ‘type 2’  like clusters were then 
characterised by the absence of GAD positivity and varying degrees of 
differences in age at diagnosis, and baseline measures of BMI, HbA1c, and 
HOMA2 measured insulin resistance and beta-cell function. The four ‘type 2’ 
clusters were named as follows; Cluster 2: severe insulin deficient diabetes 
(SIDD); Cluster 3: severe insulin resistant diabetes (SIRD); Cluster 4: mild 
obesity-related diabetes (MOD); Cluster 5: mild age-related diabetes (MARD). 
Ahlqvist and colleagues then showed potentially clinically important differences 
in disease progression and risk of complications between the clusters in 
observational follow-up, most notably a striking increase in the risk of diabetic 
kidney disease in the cluster characterised by insulin resistance (Cluster 3: 
SIRD).  
The key question for any subgroup analysis is its clinical utility, and in particular 
whether the proposed subgroups differ in response to therapy which could help 
inform treatment strategies.(2) Ahlqvist and colleagues suggested but did not 
demonstrate that the clusters could be useful to guide choice of therapy.(5) To 
date the only stratified approaches in type 2 diabetes showing large differences 
in response between treatments have used subgroups defined by routine 
clinical measures such as sex and BMI.(6)  A further key question, raised by 
van Smeden and colleagues in response to the original study, is whether 
assigning individuals to clusters has greater clinical utility for predicting 
outcomes than an approach that combines continuous clinical features to 
predict outcomes for individual patients.(7) 
We aimed to establish the clinical utility of the clusters by analysing two large 
existing trial datasets of individuals randomised to metformin, sulfonylurea and 
thiazolidinediones therapy, ADOPT and RECORD.(8, 9) In contrast to the 
observational follow-up in the original study of Scandinavian registry data, these 
trial datasets provided protocol-driven, randomised follow-up to evaluate clinical 
outcomes and differences in response to therapy. We compared the utility of the 
data-driven clusters with simpler approaches based on routine clinical 
measures available in any diabetes clinic. 
Methods 
Study population 
The primary study population comprised newly diagnosed, drug-naïve, 
individuals with type 2 diabetes participating in the ADOPT trial of glycaemic 
durability, randomised to metformin, sulfonylurea (glibenclamide) or 
thiazolidinedione (rosiglitazone) monotherapy up to five years (n=4,351).(8) 
Eligibility criteria at screening included: Age 30-75 years, fasting plasma 
glucose 7-13 mmol/l, no evidence of renal impairment (serum creatinine >114 
μmol/l for males or >106 μmol/l for females). As a replication dataset we used 
the RECORD study (n=4,447), a cardiovascular outcomes trial in individuals 
with established type 2 diabetes (mean duration of diabetes 7 years) initiating 
the same drug classes as ADOPT but as dual second-line therapy, for up to six-
years.(9) Sulfonylurea type was based on local practice (glibenclamide[18%], 
gliclazide[30%], or glimepiride[52%]), rosiglitazone was the thiazolidinedione 
used. Eligibility criteria included: Age 40-75 years, BMI >25.0 kg/m², HbA1c 
>7.0% and ≤9.0%, and no evidence of renal impairment (serum creatinine >130 
μmol/l). 
We followed individuals in both trials from randomisation until the earliest of: the 
primary outcome of the original trial; censor date, five years, or the occurrence 
of an outcome of interest. Full individual level trial data were accessed through 
Clinical Trial Data Transparency Portal (Proposal 930). 
Measurements 
We calculated HOMA2 measures of insulin resistance and beta-cell function 
using fasting C-peptide and fasting-glucose measures using the HOMA 2 
calculator.(10) In ADOPT GAD antibody positivity (yes or no) was measured 
using a commercially available radioimmunoassay.(11) In RECORD all required 
measures except GAD were measured at baseline, we calculated HOMA2 
measures using fasting insulin as fasting C-peptide was not available. Sex, age 
at diagnosis, baseline BMI and baseline HbA1c comprised the other measures 
required for cluster analysis.  
Definitions of study outcomes 
Glycaemic progression 
Glycaemic progression was defined as the change in HbA1c from one year up 
to five years (HbA1c at time t – HbA1c at one year), thus allowing for an initial 
period of treatment response up to one year. 
Kidney disease 
Chronic kidney disease (CKD) was defined as progression from normal GFR 
(eGFR ≥60 ml/min per 1.73m²) to confirmed CKD Stage 3 (two consecutive 
measures of eGFR <60 ml/min per 1.73m²). eGFR was calculated using CKD-
EPI; as a sensitivity analysis eGFR was also calculated using MDRD.(12) 
Measures of renal function were recorded at baseline, six months and annually. 
If progression was confirmed, the first of the two study visits was used to define 
CKD onset. Albuminuria was defined as progression from normal urinary 
albumin to creatinine ratio (UACR) (UACR <30 mg/g) to either microalbuminuria 
(UACR 30-300 mg/g) or macroalbuminuria (UACR ≥300 mg/g). Individuals with 
eGFR <60 and UACR ≥30 at their baseline visit were excluded from, 
respectively, the analysis of CKD and albuminuria outcomes.  
Glycaemic response 
HbA1c was evaluated as achieved HbA1c and as cumulative HbA1c reduction 
at three years as measured by area-under-the-curve (3 year AUC HbA1c). AUC 
HbA1c is equivalent to the time-updated HbA1c measure used in the UK 
Prospective Diabetes Study outcomes model.(13) Three years was chosen as 
the time point at which average AUC HbA1c was approximately equal between 
the three drugs.(8) Other time points will tend to favour a specific therapy; early 
time points will favour sulfonylureas as these agents have greater short-term 
response, whilst later time points favour thiazolidinediones which have greater 
glycaemic durability.(8) 
Statistical analysis 
Cluster analysis 
In ADOPT, we repeated the clustering approach of Ahlqvist and colleagues.(4) 
Males and females were clustered separately then pooled, continuous 
measures were mean centred and standardised, and continuous measures >5 
standard deviations from the mean were excluded. K-means clustering 
specifying four clusters was applied to the GAD-negative subset of individuals 
as K-means clustering does not incorporate binary variables; all GAD-positive 
individuals were manually assigned to a separate cluster.(4) The same R 
command (kmeansrun), number of runs (100) and measure of cluster stability 
(Jaccard coefficient >0.75 after 2000 bootstraps) were applied.(14) Once 
clusters were defined we assigned the same cluster names as in the original 
study, based on the distribution of cluster characteristics. In RECORD, we 1) 
assigned each individual to their ADOPT-derived cluster based on their 
Euclidean distance from each cluster centre; 2) repeated the cluster analysis to 
derive RECORD-specific clusters. As GAD was not available, all individuals in 
RECORD were assumed to be GAD-negative. 
Glycaemic progression 
In both trials, mean HbA1c trajectories from randomisation up to five years for 
each cluster were first estimated using a repeated-measures mixed-effects 
model, including fixed effects for study visit, assigned cluster, and a study visit 
by cluster interaction. Patient-level random effects and an unstructured 
covariance matrix were specified for this and subsequent mixed-effects models. 
All individuals within a trial were pooled, regardless of randomised therapy. To 
estimate glycaemic progression by cluster the same model was then fitted but 
with HbA1c change from one year as the outcome. We estimated the mean 
annual rate of glycaemic progression for each cluster by updating the cluster 
model to replace study visit with time as a linear covariate. Mean HbA1c by age 
was estimated using the same model but a linear term for continuous age at 
diagnosis replacing the clusters. For each model we estimated the proportion of 
variance explained (R²) by the fixed effects, the AIC, and the adequacy 
index.(15, 16) 
Kidney disease 
We compared the cumulative incidence of CKD by cluster, using Kaplan-Meier 
plots and unadjusted and baseline eGFR (a continuous linear term) adjusted 
Cox proportional hazard models with cluster as a categorical variable. We 
estimated R² and the discrimination ability (Harrell’s C-index) of the unadjusted 
cluster Cox model, compared with a Cox model with continuous baseline eGFR 
as a linear term.(16) We repeated the same analysis for time to a 30% decline 
in eGFR, and for time to albuminuria with and without adjustment for baseline 
UACR as a continuous linear term. We also compared continuous relative 
changes from baseline in eGFR and UACR progression over 0-5 years by 
cluster using a mixed-effects models with fixed effects for study visit, cluster, 
and study visit by cluster interaction. 
Glycaemic response 
We first evaluated whether HbA1c response to the three drugs differed across 
the clusters in ADOPT. Average HbA1c trajectories by drug were estimated up 
to three years for each cluster separately, using repeated-measures mixed-
effects models with fixed effects for study visit, drug, visit by drug interaction 
and visit by baseline HbA1c interaction. 3 year AUC HbA1c was estimated for 
each drug in each cluster as the integral of the area under the mean HbA1c 
trajectory using the trapezoidal rule. 
Treatment selection based on HbA1c – are clusters or clinical features 
more useful to guide therapy? 
We evaluated whether clusters were more useful than simple clinical features to 
select a drug for individual patients based on predicted 3 year AUC HbA1c. 
Models to predict HbA1c were developed in ADOPT using two strategies: A) 
using the clusters and B) using clinical features. For the clusters strategy we 
simply estimated HbA1c response for each drug at the cluster level and applied 
this to all individuals within the cluster. This strategy treats individuals within a 
cluster as homogenous for treatment response to a particular drug. For the 
clinical features strategy we combined sex and linear terms for age at 
diagnosis, baseline BMI and baseline HbA1c (the 4 routine clinical features 
informing the clusters) in a multivariable model to estimate HbA1c response 
specific to each individual for each drug. The benefit of using each strategy 
developed in ADOPT to select treatment for individuals was then tested in an 
external trial population: RECORD. 
1) Model development - ADOPT 
Strategy A) clusters model: 3 year AUC HbA1c for each drug was estimated at 
cluster level as detailed in the first step (Statistical analysis: Glycaemic 
response). Strategy B) clinical features model: 3 year AUC HbA1c, as defined 
above, was estimated for each individual based on their precise clinical 
characteristics, using multivariable repeated-measures mixed-effects models for 
each drug. Each model had HbA1c up to 3 years as the outcome with age at 
diagnosis, BMI, baseline HbA1c and study visit by baseline HbA1c interaction 
as continuous linear terms, and study visit and sex as fixed effects. Model 
performance for each strategy was assessed using R².  
2) Assessment of the treatment selection strategy in independent data – 
RECORD 
The purpose of a treatment selection model is to select the most effective 
therapies for individual patients, and therefore improve outcome at a population 
level, rather than to predict drug response accurately. This means the true test 
of a treatment selection model is whether it can robustly identify individuals 
likely to benefit from particular therapies.(17) Standard model performance 
metrics test the ability of a model to predict the outcome, and are therefore of 
limited use in this context.(17, 18) 
We therefore applied the following steps to test the effectiveness of each 
treatment selection strategy. For each individual in RECORD, we applied the 
models developed in ADOPT to obtain estimates of 3 year AUC HbA1c on each 
drug. Under Strategy A) these predictions were according to the individual’s 
assigned cluster (the same for all individuals within a cluster). Under Strategy B) 
predictions were at the individual level estimated from precise clinical features. 
For each strategy, we then applied a simple decision rule to assign individuals 
into two groups, one ‘concordant’ and one ‘discordant’. Discordant individuals 
were those randomised to a drug with a predicted 3 mmol/mol higher 3 year 
AUC HbA1c (i.e. less improvement in HbA1c) than the drug predicted to be their 
best drug; all other individuals were defined as concordant.(19) The 
effectiveness of each treatment selection strategy was determined by the 
difference in 3 year AUC HbA1c between the concordant and discordant 
groups. 3 year AUC HbA1c by concordant/discordant group was estimated as 
previously described from a mixed-effects model with study visit, 
concordant/discordant group, baseline HbA1c, study visit by 
concordant/discordant group interaction and visit by baseline HbA1c interaction 
as fixed effects. We tested the sensitivity of results to the HbA1c threshold used 
to define concordance by repeating the analysis at HbA1c thresholds of 0, 1, 2 
and 4 mmol/mol. All analyses were conducted using R version 3.4.1. 
Cardiovascular outcomes 
In RECORD we compared the time to the trial primary outcome, cardiovascular 
hospitalisation or cardiovascular death, by cluster using unadjusted and 
baseline age adjusted Cox proportional hazard models. 
Assignment of clusters in ADOPT based on cluster centre coordinates 
from the Swedish ANDIS cohort  
We assigned individuals in ADOPT to their ANDIS cluster based on their 
Euclidean distance from the cluster centres published by Ahlqvist and 
colleagues for the ANDIS cohort.(4) We then estimated glycaemic and renal 
progression and HbA1c response for each ANDIS-derived cluster, and 
compared model performance of the ADOPT defined clusters and ANDIS 
clusters. 
Role of the funding source 
The funders had no role in the study design, collection, analysis, data 
interpretation or writing of the report. The corresponding author had full access 
to all data and had final responsibility for the decision to submit for publication. 
Results 
We found the clusters identified by Ahlqvist and colleagues were reproducible in 
trial populations. 4,003 individuals in ADOPT had valid baseline measures for 
cluster assignment. Of these, 3,802 were in the intention-to-treat population and 
so were eligible for analysis of patient outcomes. We found a clear pattern of 
differences between clusters in clinical characteristics (Figure 1A, 
Supplementary Tables 1, 3, 4), and were able to assign the same cluster names 
as Ahlqvist and colleagues (Figure 1B). Clusters were reasonably stable 
(Jaccard mean range: males 0.76-0.82; females 0.69-0.82). Cluster-centre 
coordinates are shown in Supplementary Table 2. In RECORD 4,148 
individuals were eligible for cluster assignment (4,057 in intention-to-treat 
population). RECORD clusters were similar to the ADOPT clusters whether 
assigned from ADOPT or defined de-novo in RECORD (Supplementary Figure 
1). 
Average HbA1c trajectories by cluster from randomisation to five years are 
shown in the Supplementary Figure 2. Glycaemic progression from one year 
differed by cluster in ADOPT (Figure 2A), with a higher rate of progression in 
Clusters 1 (SAID), 2 (SIDD) and 4 (MOD). In RECORD only Cluster 4 (MOD) 
had a higher rate of progression (Supplementary Figure 3). However, in both 
trials older age at diagnosis was associated with a lower rate of glycaemic 
progression (mean annual difference in rate of HbA1c change per year increase 
in age at diagnosis: ADOPT -0.06 mmol/mol (95% confidence intervals -0.07 to 
-0.05; RECORD -0.05 mmol/mol (95%CI -0.06 to -0.04)) (Figure 2B, 
Supplementary Figure 3). Age at diagnosis explained a similar proportion of 
variation in progression to the clusters (ADOPT R²=0.09 age at diagnosis, 
R²=0.08 clusters; RECORD R²=0.05 age at diagnosis, R²=0.05 clusters). Other 
measures of model performance were also similar (Supplementary Table 5). 
Figure 1: Cluster distribution and cluster characteristics in ADOPT (n=4,003). SAID=severe autoimmune diabetes. 
SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. 
MARD=mild age-related diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-
IR=homoeostatic model assessment 2 estimates of insulin resistance. 
(A) Distribution of ADOPT participants according to k-means clustering  
 
(B) Distributions of HbA1c, BMI, age at diagnosis, HOMA2-B, and HOMA2-IR at baseline for each cluster 
Figure 2: Glycaemic progression by cluster in ADOPT from one to five 
years A) HbA1c change by cluster (n=3,016); B) HbA1c change by age at 
diagnosis (10th, 50th and 90% percentile of ADOPT participants) (n=3,016). Data 
are estimates from repeated measures mixed-effects models. 
 
We found differences in the incidence of CKD between clusters after excluding 
patients with pre-existing CKD; clusters 1, 3 and 5 had the highest incidence of 
CKD (Figure 3A, Supplementary Figure 4). However, there were differences 
between the clusters in baseline renal function: the clusters with the highest 
incidence of CKD had the lowest eGFR (Supplementary Table 4). After 
adjustment for baseline eGFR there was no evidence of a difference in time to 
CKD across the clusters (Table 1, Supplementary Table 6). Results were similar 
using MDRD calculated eGFR (Supplementary Table 7). In ADOPT baseline 
eGFR explained a greater proportion of variation (R²=0.18) and discrimination 
ability (C-statistic 0.90) than the clusters (R²=0.01, C-statistic=0.58); this was 
similar to results in RECORD (baseline eGFR R²=0.15, C-statistic 0.86; clusters 
R²=0.01, C-statistic=0.57). Relative change from baseline in eGFR and time to 
30% decline in eGFR did not differ by cluster (Supplementary Figures 5-6, 
Supplementary Table 8). 
There was no clear pattern of difference between clusters in baseline UACR 
(Supplementary Table 4), in incidence of albuminuria (Figure 3B, 
Supplementary Figure 4), or in relative change in UACR (Supplementary Figure 
7). After adjustment for baseline UACR time to albuminuria was shorter for 
cluster 3 (SIRD) versus cluster 2 (SIDD) in ADOPT, but not RECORD (Table 1, 
Supplementary Table 6). The clusters had no prediction and discrimination 
ability (ADOPT R²=0.00, C-statistic=0.52; RECORD R²=0.00, C-statistic=0.52), 
baseline UACR was a more useful measure (ADOPT R²=0.12, C-statistic=0.74; 
RECORD R²=0.10, C-statistic=0.73). 
  
Figure 3: Renal progression by cluster in ADOPT over five years.  
(A) Cumulative incidence of CKD Stage 3 (confirmed eGFR <60) in individuals 
with eGFR ≥60 at baseline (n=3,694)
 
(B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with 
UACR <30 mg/g at baseline (n=3,168). 
 
Patterns of HbA1c response to the different drugs differed across clusters in 
ADOPT (Figure 4, Supplementary Figure 8). There was an overall HbA1c 
benefit with thiazolidinedione therapy in cluster 3 (SIRD), and for sulfonylurea 
therapy in cluster 5 (MARD) (Table 2). However, the combined clinical features 
explained more variation in response than the clusters: R² was lower for 
Strategy A) clusters than Strategy B) clinical features (ADOPT R² clusters: 0.15 
for metformin, 0.20 sulfonylureas, 0.17 thiazolidinediones; R² clinical features: 
0.35 metformin, 0.33 sulfonylureas, 0.32 thiazolidinediones). 
Figure 4: Change in HbA1c by drug for clusters 2-5 in ADOPT over three 
years (n=3,607). Adjusted mean HbA1c over three years by drug. Grey shading 
shows 95% CIs. For cluster 1 (n=158) see Supplementary Figure 8. 
  
In the independent trial (RECORD) we found clinical features outperformed the 
clusters for treatment selection. In RECORD we tested the performance for 
treatment selection of the two strategies developed in ADOPT (Strategy A: 
selecting therapy based on predicted response to each drug at cluster level; 
Strategy B selecting therapy based on predicted response to each drug at the 
individual level based on precise clinical features (see Supplementary Table 9 
for ADOPT model coefficients for the clinical features)).  Each individual in each 
trial was assigned as concordant or discordant with the treatment selection rule 
under Strategy A) clusters and Strategy B) clinical features (Table 2, 
Supplementary Tables 10-13). 
In ADOPT, with both Strategy A) Clusters and Strategy B) clinical features, 
there was a greater overall HbA1c reduction in the concordant group compared 
with the discordant group (Figure 5A). In RECORD (validation dataset) there 
was a greater benefit in the concordant group with Strategy B) clinical features 
(Figure 5B) than Strategy A) clusters. Strategy B) clinical features outperformed 
the clusters at all HbA1c thresholds assessed to define concordant and 
discordant groups in RECORD (Supplementary Table 14). 
Figure 5: Change in HbA1c over three years in concordant and discordant 
treatment selection groups for i) clusters model and ii) clinical features model 
 
(A) ADOPT development cohort (n=3,785) 
 
 
(B) RECORD validation cohort (n=4,057) 
  
There was no evidence of differences between clusters in the risk of cardiovascular 
hospitalisation or death in RECORD after adjustment for age (Supplementary Figure 
9, Supplementary Table 15).  
Clusters assigned in ADOPT using the ANDIS cluster centre coordinates were 
broadly similar to those defined de-novo in ADOPT (Figure 1, Supplementary Figure 
10). 58% of individuals were assigned to the same cluster using both the ANDIS 
derived clusters and de-novo ADOPT clusters (Supplementary Table 16). 
Differences in outcomes by ANDIS-assigned cluster are shown in the Supplementary 
Figures 11-13. ADOPT clusters outperformed the ANDIS clusters for treatment 
response; model performance measures were similar for glycaemic and renal 
progression (Supplementary Table 17). 
Discussion 
We found the data-driven clusters of Ahlqvist and colleagues were reproducible in 
trial data. Clusters differed in glycaemic and renal progression but simple clinical 
factors features (respectively, age at diagnosis and baseline renal function) 
performed as well or better to predict progression. To our knowledge, for the first 
time we show differences by cluster in treatment response. However, clusters were 
markedly outperformed by models using simple clinical features for both the 
prediction of glucose-lowering response and for treatment selection. Overall the 
results suggest there will be greater clinical utility from modelling clinical features 
directly, rather than from using clinical features to place patients into subgroups 
(Figure 6). 
 
Even though there were restricted entry criteria for both the ADOPT and RECORD 
trials, cluster analysis defined subgroups were very similar to those seen in non-
selective Scandinavian cohorts, and subsequently Chinese and US cohorts.(4, 20) 
This suggests that if the cluster analysis is repeated in the specified way in new 
datasets it will routinely produce similar clusters.  
 
A key strength of trial data over previous observational data is the availability of 
protocol driven follow-up, meaning we were able to conduct a systematic 
assessment and demonstrate the clusters do differ in disease progression. This is a 
considerable advantage over the previously described routine follow-up where 
therapy introduction is not protocol driven.(4) Independently of therapy, clusters 1 
(SAID), 2 (SIDD) and 4 (MOD) had an increased rate of glycaemic progression. 
Differences in the development of renal failure had previously been shown in 
observational follow-up, and we replicated a faster progression of renal disease in 
clusters 3 (SIRD) and 5 (MARD), although there was no evidence of a difference in 
renal progression after accounting for baseline renal function.  
 
We were able to establish that the clusters differ in response to different glucose-
lowering therapies. This was possible due to the randomised, systematic therapy 
given. We found a particular benefit for cluster 3 (SIRD) with thiazolidinediones, and 
for cluster 5 (MARD) with sulfonylureas.  
 
The fact that clusters are reproducible and can help predict progression and 
response to therapy is important. However a key question raised in response to the 
original article is whether it is more clinically useful to use clinical features to assign a 
patient to a subgroup and then treat in a way that is best for that subgroup, or to use 
clinical features to predict patient outcomes directly using outcome-specific 
models.(7) We found simple clinical features were similar or better than the clusters 
to stratify disease progression and to personalise therapy. A simple model 
incorporating just age at diagnosis was able to predict glycaemic progression as well 
as the clusters, having been identified as a key predictor of progression in recent 
observational analysis.(21) Similarly, baseline renal function explained differences 
between the clusters in risk of renal progression.  
 
For treatment response we found that models combining four simple clinical 
measures (age, sex, baseline HbA1c and BMI) explained more variation in response 
than the clusters. However, this gives little insight into which of the two approaches 
is more useful to select between treatment options for an individual patient.(17, 18) A 
more useful test in this context is to compare the population-level effect on glycaemic 
response of applying each approach to select treatment.(18) We were able to 
directly assess this, by comparing the two approaches developed in ADOPT in an 
independent trial dataset (RECORD). This was possible as some participants in 
RECORD were randomised to the drug estimated to be ‘best’ for them using the 
ADOPT models (concordant group) whilst the remainder were randomised to a not 
‘best’ drug (discordant group). The difference in HbA1c between the two groups 
provided a measure of the population-level effect of each treatment selection 
strategy. In RECORD we found a small benefit (1.8 mmol/mol over three years) of 
selecting therapy by cluster; in contrast there was a greater benefit (3.9 mmol/mol) 
selecting treatment using the clinical features model. These results suggest that 
attempts to personalise treatment in type 2 diabetes will have most clinical utility if 
based on the use of continuous phenotypic measures, rather than subgroup 
assignment. 
 
Strengths of this study include the use of data from two large, long-term, randomised 
trials, in which we were able to not only reproduce the clustering approach of 
Ahlqvist and colleagues, but to describe diabetes progression and treatment 
response in protocol-driven follow-up. Furthermore we were able to test treatment 
selection based on clusters compared to clinical features in an independent 
validation dataset. The treatment selection rule we applied was designed to test 
clinical utility in this study, rather than to maximise outcomes for the population or 
individuals. Approaches to evaluate treatment selection strategies are not well-
developed and are the subject of on-going methodological research.(17) A limitation 
of our study is the potential non-representativeness of participants due to the original 
trial exclusion criteria. Both ADOPT and RECORD had exclusion criteria based on 
blood glucose levels and age (and BMI in RECORD); these clinical variables 
informed the cluster analysis. Despite this we found that the clusters were 
reproducible, with a pattern of differences in phenotypic measures that closely 
matched those previously reported. Given the variables informing the cluster 
analysis are not independent and are likely to be similarly correlated in most patients 
with diabetes, this reproducibility is not surprising,(7) although similarly to the original 
study we lacked data on non-white ethnicities (ADOPT was 88% Caucasian, 
RECORD 99%). Due to the design of the trials we were unable to evaluate some 
outcomes explored in the original study such as time to insulin, and we lacked power 
to evaluate other outcomes including development of end-stage renal disease. A 
further limitation was the therapy used in the trials; evaluation of heterogeneity in 
treatment response for the newer drug classes DPP4 inhibitors, SGLT2 inhibitors 
and GLP-receptor agonists would be of considerable interest. 
An important difference between this study and the original study by Ahlqvist and 
colleagues was in the analysis of renal progression. Whilst we excluded individuals 
with pre-existing kidney disease, in the Scandinavian population-based cohorts 
people with pre-existing kidney disease when diagnosed with diabetes were not 
excluded and the onset of renal dysfunction was set to the first time that an abnormal 
value was found on clinical testing post diabetes diagnosis. 
 
Precision medicine is successfully established in monogenic and neonatal diabetes, 
where it has been possible to define discrete etiological subtypes with differing 
genetic causes that have very different optimal treatment requirements.(22-24) A key 
difference from type 2 diabetes is that in these cases the subgroups have discrete 
and non-overlapping aetiologies and can be robustly defined by genetic sequencing. 
In contrast, the study of Ahlqvist and colleagues and other recent attempts to 
characterise the heterogeneity in type 2 diabetes have identified clusters with limited 
clinical utility as they are non-aetiological, overlapping, highly dependent on the 
variables used to classify them and cannot be robustly defined at an individual 
level.(4, 25) Even genetic susceptibility clusters, which do have the advantage of 
being fixed throughout life, have not led to the identification of discrete etiological 
diabetes subtypes, although they offer insight into mechanistic pathways underlying 
heterogeneity.(26)  
 
The known heterogeneity in type 2 diabetes, together with the differences we have 
observed in clinical outcomes, raises the possibility of a practical clinical application 
of precision medicine in type 2 diabetes in the near future. Our study supports the 
suggestion that the optimal approach to tailor management based on risk of 
progression and therapeutic response will be to use ‘precise’ continuous phenotypic 
measures to predict specific outcomes for individuals using multivariable models, 
rather than define subgroups and assume all individuals are homogenous within 
each subgroup.(7) In particular, individual clinical characteristics have been shown to 
have robust associations with response to specific type 2 diabetes drug options.(6, 
27-29) These studies raise the possibility that the relative glucose-lowering benefit of 
the different drugs might be identifiable by combining simple clinical measures in a 
model for treatment selection. This will require systematic assessment of 
associations between other patient features (including lifestyle factors, biomarkers 
and concomitant medications) beyond those assessed in this study. The advantage 
of such an approach is that the clinical features used are already part of routine 
clinical care. Similarly, further systematic assessment of associations between 
clinical patient features and glycaemic and renal progression will be required to 
determine whether individuals at high or low risk of progression can be robustly 
identified. 
 
The methodology we have applied in this study, harnessing existing individual-level 
trial data to test a precision medicine strategy developed in other data, offers an 
exciting, low-cost framework to evaluate novel precision medicine approaches 
without a prospective trial. Such trial datasets are increasingly available to 
researchers to answer secondary research questions.(30) The approach we used of 
a direct comparison of different approaches in an independent data set is a good 
model for defining their relative performance. When defining utility of models in future 
studies it will be important to interrogate multiple relevant outcomes as well as 
glycaemia, including cardiovascular outcomes, microvascular complications, and 
non-glycaemic effects of specific drugs including weight change and side-effects 
 
In conclusion, we have shown cluster-defined subgroups are reproducible and can 
help to define individuals that differ in the risk of diabetes progression and in 
glycaemic response to common therapeutic options. Our study demonstrates a 
‘prediction model’ approach combining phenotypic measures to predict specific 
outcomes for individual patients is likely to have greater clinical utility than subgroup 
assignment. Existing trial data offer an exciting opportunity to evaluate the potential 
of precision medicine approaches to improve patient outcomes in type 2 diabetes. 
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Supplementary Material 
Cluster assignment and characteristics (ADOPT and RECORD) 
 
Supplementary Table 1: ADOPT cluster distributions, overall and by sex (n=4,003). SAID=severe autoimmune diabetes. 
SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild 
age-related diabetes.  
 
 Male Female Overall 
Cluster N % N % N % 
1 SAID 94 4% 74 4% 168 4% 
2 SIDD 506 22% 302 18% 808 20% 
3 SIRD 448 19% 369 22% 817 20% 
4 MOD 411 18% 447 26% 858 21% 
5 MARD 844 37% 508 30% 1352 34% 
 
 
Supplementary Table 2: Cluster centre coordinates in ADOPT 
 Cluster HbA1c BMI Age at 
diagnosis 
HOMA2-B HOMA2-IR 
Females C2 (SIDD) 1.357582 -0.438702 0.209430 -0.873420 -0.508708 
 C3 (SIRD) -0.207560 0.801772 -0.048181 1.168571 1.276217 
 C4 (MOD) -0.283972 0.282755 -0.956176 -0.257172 -0.274304 
 C5 (MARD) -0.406427 -0.570389 0.751853 -0.103295 -0.383230 
 
Males C2 SIDD) 1.146754 -0.334983 -0.300259 -0.780702 -0.448964 
 C3 (SIRD) -0.419911 0.021167 0.587122 1.132740 0.960985 
 C4 (MOD) 0.102709 1.357982 -0.838457 0.480047 0.743829 
 C5 (MARD) -0.514633 -0.471697 0.276666 -0.366980 -0.603150 
  
Supplementary Table 3: ADOPT Cluster characteristics by sex (n=4,003). SAID=severe autoimmune diabetes. SIDD=severe 
insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related 
diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-IR=homoeostatic model assessment 
2 estimates of insulin resistance. 
A) Females 
 
Number of 
participants (%) 
HbA1c  
(mmol/mol) 
BMI 
kg/m2 
Age at diagnosis 
(years) 
HOMA2-B  
(%) 
HOMA2-IR  
(%) 
Cluster   Median IQR Median IQR Median IQR Median IQR Median IQR 
1 SAID 74 (4%) 59 50-65 33 28-38 59 51-64 63 46-87 2.4 1.5-3.4 
2 SIDD 302 (18%) 69 65-75 30 27-34 57 52-64 49 38-59 2.2 1.7-2.8 
3 SIRD 369 (22%) 55 49-61 39 35-43 55 49-62 102 87-125 4.3 3.8-5.0 
4 MOD 447 (26%) 54 50-58 35 31-40 46 41-50 67 54-79 2.6 2.1-3.1 
5 MARD 508 (30%) 53 49-57 30 27-33 64 58-68 70 58-83 2.5 1.9-3.0 
 
B) Males 
 
Number of 
participants (%) 
HbA1c  
(mmol/mol) 
BMI 
kg/m2 
Age at diagnosis 
(years) 
HOMA2-B  
(%) 
HOMA2-IR  
(%) 
Cluster   Median IQR Median IQR Median IQR Median IQR Median IQR 
1 SAID 94 (4%) 57 53-64 29 27-33 57 49-64 60 46-77 2.4 1.7-3.1 
2 SIDD 506 (22%) 67 63-73 29 27-32 53 46-60 49 38-59 2.3 1.8-2.8 
3 SIRD 448 (19%) 52 48-57 31 29-34 63 57-68 100 86-117 3.7 3.2-4.6 
4 MOD 411 (18%) 57 52-63 37 34-42 49 41-54 83 68-98 3.5 3.0-4.3 
5 MARD 844 (37%) 52 48-56 28 26-31 59 53-65 60 51-72 2.2 1.7-2.6 
 
 
Supplementary Table 4: Cluster characteristics for each trial population 
ADOPT (n=4,003). Median (interquartile range) unless stated. 
 1 SAID 2 SIDD 3 SIRD 4 MOD 5 MARD 
N. participants (%) 168 (4%) 808 (20%) 817 (20%) 858 (21%) 1352 (34%) 
HbA1c (mmol/mol) 58 (52-64) 67 (64-74) 53 (48-60) 55 (51-61) 53 (49-56) 
BMI (kg/m²) 30 (27-36) 29 (27-32) 34 (30-38) 36 (33-40) 29 (26-31) 
Age at diagnosis (years) 57 (49-64) 55 (48-61) 59 (53-66) 47 (41-52) 61 (55-66) 
HOMA2-B (%)* 61 (46-83) 49 (38-59) 101 (87-121) 74 (59-89) 64 (53-76) 
HOMA2-IR* 2.4 (1.6-3.3) 2.3 (1.8-2.8) 4.0 (3.4-4.7) 3.1 (2.4-3.7) 2.3 (1.8-2.7) 
Male sex (%)  94 (56%) 506 (63%)  448 (55%) 411 (48%)  844 (62%) 
Ethnicity (% White) 158 (94%) 745 (92%) 804 (98%) 801 (93%) 1327 (98%) 
Fasting glucose (mmol/l) 8.3 (7.6-9.3) 9.2 (8.4-10.2) 7.9 (7.2-8.7)  8.3 (7.5-9.2) 8.0 (7.4-8.6) 
Fasting insulin (pmol/L) 108 (70-150) 93 (72-129) 208 (150-280) 158 (114-215) 96 (72-126) 
Fasting C-peptide (nmol/L) 0.9 (0.6-1.3) 0.8 (0.7-1.0) 1.6 (1.4-1.8) 1.2 (1.0-1.4) 0.9 (0.7-1.1) 
eGFR (ml/min per 1.73m²)** 93 (82-103) 98 (87-106) 90 (77-100) 104 (96-112) 93 (82-100) 
eGFR <60 at baseline (%)** 4 (2%) 14 (2%) 41 (5%) 8 (1%) 44 (3%) 
Albuminuria (mg/g)*** 7 (4-16) 8 (4-17) 8 (4-18) 7 (4-19) 6 (4-13) 
Albuminuria ≥ 30 at baseline (%)*** 26 (16%) 126 (16%) 145 (18%) 154 (18%) 158 (12%) 
HDL (mmol/L) 1.2 (1.1-1.5) 1.2 (1.0-1.5) 1.1 (1.0-1.3) 1.1 (1.0-1.4) 1.3 (1.1-1.5) 
LDL (mmol/L) 3.0 (2.4-3.6) 3.3 (2.7-4.0 2.9 (2.4-3.6) 3.1 (2.5-3.7) 3.2 (2.6-3.8) 
ALT (U/L) 21 (16-31) 22 (17-31) 26 (19-36) 26 (18-37) 21 (16-29) 
 *Calculated with HOMA2 calculator using fasting glucose and fasting C-peptide 
** Calculated with CKD-EPI formula ***71 individuals with missing albuminuria at baseline 
 
RECORD (n=4,148; ADOPT-defined clusters). Median (interquartile range) 
unless stated. 
 1 SAID 2 SIDD 3 SIRD 4 MOD 5 MARD 
N. participants (%) NA 974 (23%) 803 (19%) 852 (21%) 1519 (37%) 
HbA1c (mmol/mol)  72 (68-75) 58 (55-64) 62 (57-66) 60 (55-63) 
BMI (kg/m²)  29 (27-32) 34 (31-37) 35 (31-37) 29 (27-31) 
Age at diagnosis (years)  50 (44-55) 54 (48-59) 44 (40-48) 56 (51-61) 
HOMA2-B (%)*  18 (13-24) 57 (45-74) 32 (23-42) 28 (20-36) 
HOMA2-IR*   1.1 (0.7-1.5) 2.4 (1.9-3.1) 1.4 (1.0-2.0) 1.0 (0.7-1.3) 
Diabetes duration (years)  7 (4-11) 5 (3-7) 6 (4-10) 5 (3-8) 
Male sex (%)  571 (59%) 361 (45%) 313 (37%) 898 (59%) 
Ethnicity (% White)  964 (99%) 795 (99%) 841 (99%) 1510 (99%) 
Fasting glucose (mmol/l)  11 (10-13) 9 (8-10) 10 (8-11) 9 (8-10) 
Fasting insulin (pmol/L)  48 (32-66) 114 (91-146) 67 (48-91) 45 (32-61) 
Fasting C-peptide (nmol/L)  NA NA NA NA 
eGFR (ml/min per 1.73m²)**  100 (91-106) 97 (88-105) 106 (99-112) 96 (87-102) 
eGFR <60 at baseline (%)**  13 (1%) 28 (3%) 9 (1%) 30 (2%) 
Albuminuria (mg/g)***  9 (5-25) 9 (5-23) 9 (5-24) 8 (4-17) 
Albuminuria ≥ 30 at baseline (%)***  190 (22%) 142 (20%) 149 (20%) 209 (16%) 
HDL (mmol/L)  1.2 (1.0-1.4) 1.1 (0.9-1.3) 1.2 (1.0-1.4) 1.2 (1.0-1.4) 
LDL (mmol/L)  3.4 (2.8-4.0) 3.2 (2.5-3.8) 3.2 (2.6-3.8) 3.3 (2.6-3.8) 
ALT (U/L)  25 (19-36) 29 (21-41) 26 (19-39) 23 (17-31) 
*Calculated with HOMA2 calculator using fasting glucose and fasting insulin as fasting C-peptide not 
available 
** Calculated with CKD-EPI formula, 2 individuals missing eGFR at baseline ***479 individuals with 
missing albuminuria at baseline  
Supplementary Figure 1: clusters characteristics in RECORD. Cluster distribution and 
cluster characteristics (n=4,148). RECORD participants assignment and distributions of 
baseline clinical characteristics according to k-means clustering (A) Clusters derived in ADOPT 
and assigned to RECORD participants (B) Clusters derived in RECORD and assigned to 
RECORD participants. 
SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe 
insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related 
diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-
IR=homoeostatic model assessment 2 estimates of insulin resistance. 
(A) ADOPT derived clusters 
  
 
(B) RECORD derived clusters 
 
 
 
 
 
 
 
 
  
Glycaemic progression 
 
Supplementary Figure 2: HbA1c over time from randomisation by cluster 
in ADOPT (n=3,802). 
   
 
Supplementary Figure 3: HbA1c in RECORD  
(A) HbA1c over time from randomisation by cluster (n=4,057);  
  
  
Supplementary Figure 3 (cont.): HbA1c in RECORD.  
(B) Glycaemic progression from 1 year by ADOPT derived cluster (n=3,586); 
(C) Glycaemic progression from 1 year by age at diagnosis (10th, 50th and 90% 
percentile of RECORD participants) (n=3,586). Data are estimates from 
repeated measures mixed effects models.  
 
 
Supplementary Table 5: Glycaemic progression model performance 
measures to compare model using clusters and model using age at 
diagnosis. A higher adequacy index suggests a better model (calculated as 
model LR x² / Combined model LR x²) 
 
A) ADOPT 
 
  R² AIC LR x² Adequacy Index 
Clusters 0.084 221404 1225 0.95 
Age at diagnosis 0.088 221318 1210 0.94 
Combined model (clusters + age at 
diagnosis) 
0.093 221371 1292 1.00 
 
 
B) RECORD 
 
  R² AIC LR x² Adequacy Index 
Clusters 0.048 274658 1065 0.89 
Age at diagnosis 0.052 274624 1099 0.92 
Combined model (clusters + age at 
diagnosis) 
0.055 274642 1196 1.00 
 
  
Renal progression 
 
Supplementary Figure 4: Renal progression by cluster in RECORD 
(clusters derived from ADOPT) 
(A) Cumulative incidence of CKD Stage 3 (confirmed eGFR <60) in individuals 
with eGFR ≥60 at baseline (n=4,066). eGFR calculated using CKD-EPI formula. 
 
(B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with 
UACR <30 mg/g at baseline (n=2,979).  
 
Supplementary Table 6: Risk of renal progression by cluster in RECORD 
(clusters derived from ADOPT) 
(A) Time to CKD Stage 3 (n=4,066). eGFR calculated using CKD-EPI formula. 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to CKD 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 961 2551 17 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 775 2789 22 1.12 (0.60-2.11) 0.96 (0.51-1.81) 
    C4 (MOD) 842 2811 6 0.31 (0.12-0.78) 0.57 (0.22-1.45) 
    C5 (MARD) 1488 5658 55 1.37 (0.79-2.36) 1.16 (0.67-2.00) 
*Adjusted for baseline eGFR 
(B) Time to albuminuria (n=2,979) 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to albuminuria 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 680 1679 103 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 580 1860 113 1.04 (0.80-1.36) 1.02 (0.78-1.34) 
    C4 (MOD) 605 1869 90 0.82 (0.62-1.09) 0.82 (0.62-1.09) 
    C5 (MARD) 1114 3906 188 0.85 (0.66-1.08) 0.92 (0.72-1.17) 
*Adjusted for baseline UACR 
  
Supplementary Table 7: Time to CKD Stage 3. eGFR calculated using MDRD 
formula. 
 (A) ADOPT (n=3,650) 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to CKD 
Cluster           
    C1 (SAID) 152 492 7 3.00 (1.16-7.72) 1.67 (0.64-4.32) 
    C2 (SIDD) 748 2235 11 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 729 2427 35 2.99 (1.53-5.92) 1.65 (0.84-3.26) 
    C4 (MOD) 799 2406 11 0.93 (0.40-2.14) 1.33 (0.57-3.06) 
    C5 (MARD) 1222 4325 41 2.00 (1.03-3.90) 1.52 (0.78-2.97) 
*Adjusted for baseline eGFR 
(B) RECORD (n=4,032) 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to albuminuria 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 956 2528 20 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 769 2753 30 1.31 (0.74-2.31) 1.10 (0.91-1.94) 
    C4 (MOD) 838 2781 15 0.66 (0.34-1.28) 0.98 (0.50-1.91) 
    C5 (MARD) 1469 5570 74 1.58 (0.96-2.59) 1.41 (0.86-2.32) 
*Adjusted for baseline eGFR 
  
Supplementary Figure 5: Relative change in eGFR from baseline, by 
cluster. eGFR calculated using CKD-EPI formula. Estimates are from mixed 
effects models. 
A) ADOPT (n=3,694) 
 
B) RECORD (n=4,066) 
 
  
Supplementary Figure 6: Cumulative incidence of 30% relative change in 
eGFR from baseline, by cluster. eGFR calculated using CKD-EPI formula. 
A) ADOPT (n=3,694) 
 
B) RECORD (n=4,066) 
 
  
Supplementary Table 8: Risk of 30% relative change in eGFR from 
baseline by cluster. eGFR calculated using CKD-EPI formula. 
(A) ADOPT (n=3,694) 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to 30% relative change in eGFR 
Cluster           
    C1 (SAID) 155 508 7 0.88 (0.39-1.97) 0.78 (0.35-1.77) 
    C2 (SIDD) 758 2239 35 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 743 2452 51 1.33 (0.87-2.05) 1.16 (0.75-1.79) 
    C4 (MOD) 808 2387 34 0.92 (0.57-1.48) 1.05 (0.65-1.69) 
    C5 (MARD) 1230 4359 54 0.79 (0.51-1.20) 0.72 (0.47-1.10) 
*Adjusted for baseline eGFR 
(B) RECORD (n=4,066) 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to 30% relative change in eGFR 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 961 2547 58 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 775 2771 57 0.83 (0.58-1.20) 0.78 (0.54-1.12) 
    C4 (MOD) 842 2773 40 0.59 (0.39-0.88) 0.74 (0.49-1.11) 
    C5 (MARD) 1488 5625 122 0.85 (0.62-1.16) 0.78 (0.57-1.07) 
*Adjusted for baseline eGFR 
Supplementary Figure 7: Relative change in urinary albumin to creatinine 
ratio from baseline, by cluster. Estimates are from mixed effects models with 
UACR modelled on log scale. 
A) ADOPT (n=3,168) 
 
  
B) RECORD (n=2,979) 
  
HbA1c response 
 
Supplementary Figure 8: Changes in HbA1c (ADOPT trial, n=3,785). 
Adjusted mean HbA1c over 3 years by drug for clusters 1-5 (repeated 
measures mixed model). Grey shading shows 95% CIs. 
 
 
Supplementary Table 9: Beta coefficients from mixed effects models for clinical features, 
by drug. For continuous features beta coefficients represent the change in HbA1c response for 
a 1-unit increase in the clinical feature. A negative coefficient indicates a higher value of the 
clinical feature is associated with greater reduction in HbA1c.  
 
 Metformin Sulfonylureas Thiazolidinediones 
Baseline HbA1c (time 0)* 0.69 (0.66;0.72) 0.59 (0.55;0.63) 0.69 (0.65;0.73) 
BMI -0.02 (-0.07;0.03) 0.03 (-0.02;0.09) -0.11 (-0.16;-0.06) 
Age at diagnosis 0.00 (-0.03;0.03) -0.02 (-0.05;0.01) -0.02 (-0.06;0.01) 
Sex: Male 0.53 (-0.07;1.13) -1.54 (-2.19;-0.89) 0.59 (-0.06;1.23) 
*Full baseline HbA1c:study visit interaction terms not reported for brevity.  
Treatment selection 
 
 
 
Supplementary Table 10 
 
ADOPT number of concordant individuals, by cluster, for treatment 
selection at 3 years based on Strategy A) treatment selection based on 
clusters 
 
 
 
Discordant Concordant 
Cluster 
  
    C1 (SAID) 
93 65 
    C2 (SIDD) 
257 502 
    C3 (SIRD) 
510 265 
    C4 (MOD) 
272 539 
    C5 (MARD) 
838 424 
 
 
 
 
Supplementary Table 11 
 
ADOPT number (%) of concordant individuals, by drug at 3 years, for 
 
Strategy A) treatment selection based on clusters 
 
 Discordant Concordant 
Overall 1970 (52%) 1795 (48%) 
By randomised drug:   
    Metformin 702 (55%) 569 (45%) 
    Sulfonylureas 555 (45%) 672 (55%) 
    Thiazolidinedione 713 (56%) 554 (44%) 
 
 
Strategy B) treatment selection based on clinical features 
 
 Discordant Concordant 
Overall 1227 (33%) 2538 (67%) 
By randomised drug:     
    Metformin 225 (18%) 1046 (82%) 
    Sulfonylureas 455 (37%) 772 (63%) 
    Thiazolidinedione 547 (43%) 720 (57%) 
 
 
  
Supplementary Table 12 
 
RECORD number of concordant individuals, by cluster, for treatment 
selection at 3 years based on Strategy A) treatment selection based on 
clusters 
 Discordant Concordant 
Cluster   
    C1 (SAID) - - 
    C2 (SIDD) 455 493 
    C3 (SIRD) 406 386 
    C4 (MOD) 239 594 
    C5 (MARD) 1121 363 
 
 
 
Supplementary Table 13 
 
RECORD number (%) of concordant individuals, by drug at 3 years, for 
a) treatment selection based on clusters 
 
Strategy A) treatment selection based on clusters 
 
 Discordant Concordant 
Overall 2221 (55%) 1836 (45%) 
By randomised drug:   
    Metformin 540 (54%) 463 (46%) 
    Sulfonylureas 469 (46%) 546 (54%) 
    Thiazolidinedione 1212 (59%) 827 (41%) 
 
 
Strategy B) treatment selection based on clinical features 
 
 Discordant Concordant 
Overall 1117 (28%) 2940 (72%) 
By randomised drug:   
    Metformin 23 (2%) 980 (98%) 
    Sulfonylureas 494 (49%) 521 (51%) 
    Thiazolidinedione 600 (29%) 1439 (71%) 
 
  
Supplementary Table 14: Cumulative HbA1c reduction at 3 years in 
concordant and discordant treatment selection groups using different 
HbA1c thresholds to define concordant/discordant groups, for clusters 
model and clinical features model (RECORD n=4,057) 
 
 
HbA1c threshold 
(mmol/mol 
Clusters 3 Year AUC HbA1c Continuous features 3 Year AUC HbA1c 
 Concordant Discordant Concordant Discordant 
0 -18.0 (-19.6;-16.4) -15.0 (-16.1;-14.0) -18.3 (-20.0;-16.7) -14.8 (-15.9;-13.8) 
1 -17.0 (-18.4;-15.6) -15.2 (-16.3;-14.0) -18.3 (-19.6;-16.9) -13.9 (-15.1;-12.7) 
2 -17.0 (-18.4;-15.6) -15.2 (-16.3;-14.0) -17.6 (-18.7; -16.5) -13.2 (-14.7;-11.8) 
3 -16.9 (-18.2;-15.6) -15.1 (-16.3;-13.9) -17.0 (-18.0;-15.9) -13.1 (-14.9;-11.4) 
4 -16.9 (-18.1;-15.7) -14.9 (-16.2;-13.6) -16.6 (-17.5;-15.6) -13.4 (-15.4;-11.4) 
 
  
Cardiovascular outcomes (RECORD trial) 
 
Supplementary Figure 9: Cumulative incidence of cardiovascular 
hospitalisation or death, by ADOPT-derived cluster. 
RECORD (n=4,057) 
 
 
Supplementary Table 15: Risk of cardiovascular hospitalisation or death 
by cluster in RECORD (clusters derived from ADOPT) 
RECORD (n=4,057) 
  
No. 
Person years 
at risk 
Events Hazard ratio (95% CI) 
        Unadjusted Adjusted* 
Time to cardiovascular hospitalisation or death 
Cluster           
    C1 (SAID) NA NA NA NA NA 
    C2 (SIDD) 948 3172 88 1.00 (ref) 1.00 (ref) 
    C3 (SIRD) 792 3038 94 1.11 (0.83-1.49) 1.06 (0.79-1.41) 
    C4 (MOD) 833 3141 62 0.71 (0.51-0.98) 1.02 (0.73-1.43) 
    C5 (MARD) 1484 5996 161 0.97 (0.74-1.25) 0.79 (0.61-1.03) 
*Adjusted for age at trial entry 
  
Application of clusters from the Swedish All New Diabetics in Scania 
cohort (ANDIS) to ADOPT 
 
Supplementary Figure 10: Characteristics of clusters assigned in ADOPT 
from the cluster centre coordinates in ANDIS (n=4,003). Cluster centre 
coordinates originally published in Table S3, Ahlqvist et al., Lancet Diabetes 
Endocrinology 2018;6:361-69.  
SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. 
SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. 
MARD=mild age-related diabetes. HOMA2-B=homoeostatic model assessment 
2 estimates of β-cell function. HOMA2-IR=homoeostatic model assessment 2 
estimates of insulin resistance. 
(A) Distribution of ADOPT participants according to ANDIS clustering  
 
(B) Distributions of HbA1c, BMI, age at diagnosis, HOMA2-B, and HOMA2-
IR at baseline for each ANDIS-derived cluster. 
 
 
Supplementary Table 16: Concordance between clusters defined de-novo 
in ADOPT and clusters assigned in ADOPT from ANDIS cluster centre 
coordinates 
  ANDIS clusters 
   ADOPT clusters     C1 (SAID) C2 (SIDD) C3 (SIRD) C4 (MOD) C5 (MARD) 
    C1 (SAID) 100% 0% 0% 0% 0% 
    C2 (SIDD) 0% 56% 9% 25% 9% 
    C3 (SIRD) 0% 1% 59% 2% 38% 
    C4 (MOD) 0% 2% 12% 43% 43% 
    C5 (MARD) 0% 11% 3% 18% 68% 
  
Supplementary Figure 11: Glycaemic progression by cluster in ADOPT 
from one to five years using ANDIS-derived clusters (n=3,016) 
 
 
 
Supplementary Figure 12: Renal progression by cluster in ADOPT over 
five years using ANDIS-derived clusters. 
(A) Cumulative incidence of CKD Stage 3 (confirmed eGFR <60) in individuals 
with eGFR ≥60 at baseline (n=3,694). eGFR calculated using CKD-EPI formula. 
 
  
(B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with 
UACR <30 mg/g at baseline (n=3,168). 
 
 
 
Supplementary Figure 13: Change in HbA1c by drug for each cluster in 
ADOPT over three years using ANDIS-derived clusters (n=3,785). Adjusted 
mean HbA1c over three years by drug. Grey shading shows 95% CIs.  
 
 
  
Supplementary Table 17: Model performance measures to compare 
clusters defined de-novo in ADOPT and clusters assigned in ADOPT from 
ANDIS cluster centre coordinates  
A) Glycaemic progression from one to five years (n=3,016) 
  R² AIC 
ADOPT clusters 0.084 221404 
ANDIS clusters 0.078 221446 
 
B) Time to CKD Stage 3 (confirmed eGFR <60) in individuals with eGFR ≥60 at 
baseline (n=3,694). eGFR calculated using CKD-EPI formula. 
  C-statistic R² 
ADOPT clusters 0.58 0.01 
ANDIS clusters 0.59 0.01 
 
C) Time to albuminuria (UACR ≥30 mg/g) in individuals with UACR <30 mg/g at 
baseline (n=3,168). 
  C-statistic R² 
ADOPT clusters 0.52 0.002 
ANDIS clusters 0.52 0.003 
 
D) Explained variation (R²) in treatment response (changes in HbA1c over 3 
years)  
  Metformin Sulfonylurea Thiazolidinedione 
ADOPT clusters 0.15 0.20 0.17 
ANDIS clusters 0.10 0.12 0.09 
 
 
 
